CA-VEEVA-SYSTEMS-INC.
Veeva Systems (NYSE: VEEV) today announced at Veeva Summit Online a new capability in Veeva Vault PromoMats to speed the digital submission of promotional materials for accelerated approval products. Vault PromoMats will automatically generate submission-ready forms to simplify packaging promotional materials to send via eCTD (Electronic Common Technical Document) to the U.S. Food and Drug Administration (FDA). Brand marketing teams can reduce time in preparing content in a compliant digital format and getting it ready for FDA submissions.
“Veeva is helping life sciences stay ahead of evolving regulations and accelerate the shift toward digital,” said Pooja Ojala, vice president of commercial content at Veeva. “Veeva Vault PromoMats will allow brand marketing teams to create digital submissions faster and easier, while maintaining compliance with federal requirements.”
Last year the FDA finalized guidance on electronic submission via eCTD for postmarketing and accelerated approval products. Veeva is enabling customers to meet the FDA’s fast-approaching June 2021 deadline that will make it mandatory to submit promotional materials electronically.
Vault PromoMats automates preparing submission-ready content to make it faster and easier for brand marketing teams to package websites, emails, and other content for FDA review. Automatic linking of promotional materials and references simplifies building a package consistent with eCTD data requirements. Templatized forms allow customers to create a binder of relevant documents in the right structure and naming format for faster health authority submission.
In other news today, Veeva announced Veeva Link for KAM, a new solution that gives commercial and medical teams accurate customer data and real-time insights for key account management. Read today’s press release to learn more.
Vault PromoMats is an advanced application that combines digital asset management with medical, legal, and regulatory review to improve global reuse of promotional materials and maintain compliance from content creation through distribution. The new capability to generate submission-ready forms for accelerated approval products is planned for availability in December 2020.
Learn how Vault PromoMats allows brand marketing teams to reduce time and errors when creating digital submissions at Veeva Summit Online, 9-10 June. The event is only open to life sciences industry professionals. Register for the virtual event and on-demand sessions at veeva.com/Summit .
Additional Information
For more on Veeva Vault PromoMats, visit: veeva.com/eu/PromoMats
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
